Drugs / SYS6041
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07714668 | Aug 2026 → Apr 2028 expected | ovarian cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07714668 ↗ |
| Route | Intravenous | “SYS6041: RP2D dose, ivgtt, Q3W” NCT07714668 ↗ |